摘要
目的分析非小细胞肺癌(NSCLC)癌组织中ERCC1的表达状况及其与NSCLC的临床病理特征的关系。方法采用免疫组织化学法检测6 4例初治中晚期NSCLC患者癌组织中ERCC1基因的表达情况。结果 ERCC1表达的阳性率为4 3.8%,其表达与吸烟有密切关系,在吸烟组中的阳性率(27.8%)显著低于不吸烟组(6 4.3%)(x^2=8.5 3 0,P=0.0 0 4)。随着原发灶和疾病分期增加,ERCC1的阳性率有上升的趋势,但组间比较差异均无显著性(均为P>0.0 5)。ERCC1在腺癌和低分化癌组中的阳性率分别高于鳞癌和高、中分化组,但差异无显著性(P>0.0 5)。ERCC1的表达与年龄、性别和淋巴结转移状况等均未见显著性关联(均为P>0.0 5)。结论 ERCC1表达与NSCLC的一些临床病理学特征密切相关。
Objective To investigated the association between the expression of DNA repair gene ERCC1 with the clinicopathology characteristics in patients with advanced noninitial chemotherapy treatment non-small cell lung cancer ( NSCLC ). Methods The ERCC1 expression in 64 NSCLC patients was examined with the method of immunohistochemistry, expression differences of ERCC1 and its relationship with the patients clinicopathology characteristics were analyzed. Results There were 28 cases expressing ERCC1 (43.8%). Expression rates of ERCC1 in smokers was 27. 8% and was significantly lower than that in non-smokers (64.3%). The expression of ERCC1 in lung adenocarcinomas were lightly higher than squamous cell carcinomas,but the different was not significant. There were no significant differences between the expression of ERCC1 and the different TNM stages,gender,ages and pathological classification. Conclusion In non-small cell lung cancer,expression of ERCCl was significantly higher in smokers than in non-smokers.
出处
《中国医学文摘(肿瘤学)》
2008年第4期346-348,共3页
Journal of Chinese Medical Abstracts·Oncology
基金
广西自然科学基金项目(桂科自0832234)
关键词
肺癌
ERCC1
免疫组织化学
Lung cancer
Excision repair cross eomplementation group 1 Immunohistochemistry